Is Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines? [Yahoo! Finance]
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
Tango Therapeutics (TNGX) had its "buy" rating reaffirmed by B. Riley Financial, Inc..
Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX) [Yahoo! Finance]
Tango Therapeutics (TNGX) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $30.00 price target on the stock.